Jane Wasman - Net Worth and Insider Trading
Jane Wasman Net Worth
The estimated net worth of Jane Wasman is at least $13 dollars as of 2024-11-13. Jane Wasman is the President, Intl and GC of Acorda Therapeutics Inc and owns about 979 shares of Acorda Therapeutics Inc (ACORQ) stock worth over $13. Details can be seen in Jane Wasman's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jane Wasman has not made any transactions after 2019-12-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Jane Wasman
Jane Wasman Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jane Wasman owns 4 companies in total, including Rigel Pharmaceuticals Inc (RIGL) , SELLAS Life Sciences Group Inc (SLS) , and Acorda Therapeutics Inc (ACORQ) among others .
Click here to see the complete history of Jane Wasman’s form 4 insider trades.
Insider Ownership Summary of Jane Wasman
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RIGL | Rigel Pharmaceuticals Inc | 2022-05-20 | director |
| SLS | SELLAS Life Sciences Group Inc | 2019-03-14 | director |
| ACORQ | Acorda Therapeutics Inc | 2019-12-02 | Exec V Pres & Gen Cnsl & Sec |
 | | 2020-11-12 | director |
Jane Wasman Latest Holdings Summary
Jane Wasman currently owns a total of 1 stock. Jane Wasman owns 979 shares of Acorda Therapeutics Inc (ACORQ) as of December 2, 2019, with a value of $13.
Latest Holdings of Jane Wasman
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ACORQ | Acorda Therapeutics Inc | 2019-12-02 | 979 | 0.01 | 13 |
Holding Weightings of Jane Wasman
Jane Wasman Form 4 Trading Tracker
According to the SEC Form 4 filings, Jane Wasman has made a total of 1 transactions in Acorda Therapeutics Inc (ACORQ) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Acorda Therapeutics Inc is the sale of 19 shares on December 2, 2019, which brought Jane Wasman around $3,563.
Insider Trading History of Jane Wasman
- 1
Jane Wasman Trading Performance
Jane Wasman Ownership Network
Ownership Network List of Jane Wasman
Ownership Network Relation of Jane Wasman
Jane Wasman Owned Company Details
What does Rigel Pharmaceuticals Inc do?
Who are the key executives at Rigel Pharmaceuticals Inc?
Jane Wasman is the director of Rigel Pharmaceuticals Inc. Other key executives at Rigel Pharmaceuticals Inc include EVP & Chief Financial Officer Dean L Schorno , Sr VP of Bus Dev and Com Ops Raul R Rodriguez , and EVP & Chief Commercial Officer David A Santos .
Rigel Pharmaceuticals Inc (RIGL) Insider Trades Summary
Over the past 18 months, Jane Wasman made no insider transaction in Rigel Pharmaceuticals Inc (RIGL). Other recent insider transactions involving Rigel Pharmaceuticals Inc (RIGL) include a net sale of 52,894 shares made by Raul R Rodriguez , a net sale of 14,519 shares made by David A Santos , and a net sale of 12,628 shares made by Dean L Schorno .
In summary, during the past 3 months, insiders sold 0 shares of Rigel Pharmaceuticals Inc (RIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 8,004 shares of Rigel Pharmaceuticals Inc (RIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 8,004 shares.
Rigel Pharmaceuticals Inc (RIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Rigel Pharmaceuticals Inc Insider Transactions
Jane Wasman Mailing Address
Above is the net worth, insider trading, and ownership report for Jane Wasman. You might contact Jane Wasman via mailing address: C/o Acorda Therapeutics, Inc., 420 Saw Mill River Road, Ardsley Ny 10502.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
